HC Wainwright Brokers Increase Earnings Estimates for MSLE

Satellos Bioscience Inc. (NASDAQ:MSLE) – Analysts at HC Wainwright boosted their FY2029 earnings per share (EPS) estimates for shares of Satellos Bioscience in a research report issued to clients and investors on Thursday, July 9th. HC Wainwright analyst A. He now anticipates that the company will earn ($0.86) per share for the year, up from their prior forecast of ($1.16). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Satellos Bioscience’s current full-year earnings is ($1.69) per share. HC Wainwright also issued estimates for Satellos Bioscience’s FY2030 earnings at $0.93 EPS.

Satellos Bioscience (NASDAQ:MSLE) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.02).

Several other research analysts also recently commented on the company. Wall Street Zen upgraded Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Satellos Bioscience in a research report on Monday, May 11th. Guggenheim began coverage on shares of Satellos Bioscience in a report on Tuesday, April 28th. They set a “buy” rating and a $23.00 target price on the stock. Canaccord Genuity Group upgraded Satellos Bioscience to a “moderate buy” rating in a research note on Thursday, May 21st. Finally, Wells Fargo & Company set a $18.00 price target on Satellos Bioscience in a research report on Thursday. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $19.75.

Satellos Bioscience Stock Performance

Shares of MSLE stock opened at $9.79 on Monday. Satellos Bioscience has a 52-week low of $4.64 and a 52-week high of $13.39. The company has a market cap of $203.93 million, a PE ratio of -6.12 and a beta of 1.53. The firm has a 50-day moving average price of $6.99.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.